←Back to Expert Scholars
Translational Medicine / 转化医学Drug Repurposing, AI Discovery
Andrew Hopkins
DPhil
🏢Exscientia🌐UK
Founder and CEO
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Andrew Hopkins founded Exscientia and pioneered AI-based polypharmacology that informs drug repurposing across oncology. His computational platforms identify existing drugs with new oncology targets. He holds a chair at the University of Dundee.
Share:
🧪Research Fields 研究领域
AI drug discovery
polypharmacology
repurposing
target prediction
cancer pharmacology
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Andrew Hopkins 的研究动态
Follow Andrew Hopkins's research updates
留下邮箱，当我们发布与 Andrew Hopkins（Exscientia）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment